The Russian Center for Epidemiology and Microbiology Gamaleya has already started clinical trials with its vaccine against the Sputnik V coronavirus in risk groups, as announced by the director of the Russian Direct Investment Fund (FIDR), Kiril Dimitriev.
“Right now, the Gamaleya Center has started several clinical trials in risk groups, which means they are testing it (the vaccine) in the elderly,” said Dimitriev. The director of FIDR said that the results of these tests will make it possible to determine whether or not the Sputnik V vaccine is safe for the elderly, stressing that he does not believe the drug will have any negative effects on the elderly.
“My mother and father, who are 74 years old, have also been vaccinated as volunteers and are completely fine,” he added. Russia officially registered the Sputnik V coronavirus vaccine on Aug. 11, which is currently in the third phase of studies. According to its developers, Sputnik V generates immunity for up to two years.
The FIDR-funded vaccine consists of two components: the first is based on the human adenovirus type 26 and the second is based on the recombinant human adenovirus type 5. The vaccine is given twice with an interval of at least 21 days.